Skip to main content Skip to home page

Deaconess MyChart

Access Deaconess MyChart

Access Deaconess MyChart

Sign In
New User? Sign up now
Download For Your Mobile Device
  • Android
  • Apple


Indication: Breast Cancer

Trial name
NRG-BR003-A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
Trial code:  NRG-BR003   NCT02488967

Trial name
SWOG S1418-Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Trial code: SWOG S1418   NCT02954874

Trial name
CTSU S1207-Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Description: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Trial code: CTSU S1207   NCT01674140

Indication: All Cancer

Trial name
ECOG-ACRIN EAY131 (MATCH)-Molecular Analysis for Therapy Choice (MATCH)

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.

Trial code: ECOG-ACRIN EAY131 (MATCH)   NCT02465060


Indication: Trial Screening Tool

Trial name
DCP-001-Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
The purpose of this project is to understand why patients do not participate in clinical trials. This information will help researchers design future studies. Also, to address the reasons people do not participate, especially young adults and teenagers, older people and minorities. In addition, personal and medical information will be collected to help understand differences in treatment and treatment outcomes among these populations.
Trial code: DCP-001                     


Contact Us

Top Back to top